Review of HLA-B27 Save

Know-it-now

• HLA-B*27 penetrance is low (<5%) in the general population.
• Even as a strong risk marker (80–90%) for AS, there are > 100 other genes that contribute (IL-23 pathway genes are next most important).
• Phenotype depends on age: children present with peripheral arthritis/enthesitis (75–90%) while 75–80% of adults present axially.
• There are new AxJSpA classification criteria: needed as children rarely meet adult 3-month back-pain criteria.
• B*27 predicts divergent treatment responses: better TNF-inhibitor response in adult AxSpA but worse response in pediatric ERA with axial disease.
• Targeted TRBV9+ T-cell depletion (BCD-180) is the first mechanism-based therapy to reach Phase 2, validating the arthritogenic-peptide hypothesis, though its modest ELEFTA effect size versus the initial case report tempers enthusiasm pending further data.

What’s New? HLA-B27 remains the dominant genetic link to spondyloarthritis (SpA) across the age spectrum, but B27 related clinical expression diverges between children and adults. New mechanistic data on autoreactive T cells, HLA-B27 misfolding, and gut-joint trafficking point to new plausible, targetable pathways.

Epidemiology.  HLA-B27 is present in 80–90% of patients with ankylosing spondylitis (AS) versus <10% of healthy controls, making it the single strongest genetic risk factor in rheumatology. Yet penetrance is low: fewer than 5% of HLA-B27 carriers ever develop SpA, and over 100 additional genes/genomic regions contribute to AS susceptibility. Overall AS heritability exceeds 90%, but only ~30% has been genetically mapped — 20% attributable to HLA-B*27 itself, 8–10% to other risk loci (notably IL-23 pathway genes: IL23R, TYK2, STAT3, IL12B, IL6R, with CARD9 implicated in IL-23 production). Disease risk conferred by the allele first manifests around age 6, peaks at 20–30 yrs., and drops sharply after 45 yrs.

HLA-B27 frequency varies substantially by SpA subtype and age. In juvenile SpA (JSpA), HLA-B27 positivity ranges 40–80% across cohorts and correlates with active joint count, sacroiliitis, and disease activity. In juvenile PsA, however, prevalence is only 10–12%, with no correlation to axial disease, distinguishing it mechanistically from enthesitis-related arthritis (ERA).

Over 160 HLA-B27 subtypes exist; B27:05 (most prevalent globally) confers risk in all populations studied, B27:06 and B27:09 are generally non-pathogenic, and B27:04 may confer heightened risk in East Asian and South Indian populations.

Disease associations. HLA-B27 does not independently predispose to IBD or psoriasis, but selectively increases risk for axial arthritis and acute anterior uveitis (AAU), regardless of the SpA subtype it's paired with. AAU occurs in 25–30% of adult SpA patients versus ~10% of pediatric patients, and is strongly HLA-B27–linked in both. A key pediatric caveat: in children <6 years old, ANA positivity — independent of B*27 status — predicts asymptomatic chronic uveitis, mandating frequent ophthalmologic screening in this subgroup regardless of genotype.

Clinically, HLA-B27 carriage predicts worse outcomes across the age spectrum: poorer prognosis and paradoxically better TNF-inhibitor response in adult AxSpA, but less effective TNF inhibition in pediatric ERA, particularly with axial involvement. An 18-year Nordic JIA follow-up confirmed B27 links to more frequent sacroiliac/hip/subtalar arthritis and lower remission, especially in males.

Mechanistic advances. Several novel pathogenic mechanisms are reviewed as they may have future therapeutic implications.

1. Arthritogenic peptide presentation  Clonal CD8+ T cells bearing a conserved TCR motif (G(T/V/I/L)(Y/F)STDTQ, TRBV9-associated) that recognizes HLA-B*27-bound self-peptides resembling microbial sequences (e.g., an E. coli/Salmonella/Shigella inner-membrane protein epitope). This has moved from bench to bedside: targeted anti-TRBV9 T-cell depletion (BCD-180) showed efficacy in a case report and a subsequent placebo-controlled Phase 2 trial (ELEFTA), though effect size was more modest than the initial report.
2. Aberrant B*27 dimer signaling — β2m-free HLA-B*27 heavy-chain dimers engage KIR3DL2 on NK and CD4+ T cells, driving anti-apoptotic Th17 expansion and IL-17A production — a mechanism also demonstrated in pediatric ERA synovial fluid.
3. ER stress/misfolding — Slow B*27 folding promotes aberrant disulfide-linked dimers and UPR activation; in spinal enthesis-derived MSCs, this pathway enhances mineralization and bone formation in vivo, offering a mechanistic explanation for radiographic progression in AxSpA — though UPR's role via CHOP remains contradictory in rat models (knockout worsened, not improved, colitis).
4. The gut-joint axis rounds out pathogenesis: gut-homing α4β7+ CD8+ T cells bearing the arthritogenic TCR motif are enriched in AxSpA blood/synovium, and >50% of YEIH-tetramer-positive clones co-express gut-homing markers — suggesting these autoreactive cells are gut-educated.